Fortrea Holdings Inc
Company Profile
Business description
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Contact
8 Moore Drive
DurhamNC27713
USAT: +1 877 495-0816
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14,300
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
stocks
Our top ASX picks in every sector
stocks
Tesla: Shares fall as deliveries come in below consensus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,223.93 | 315.19 | 3.99% |
| DAX 40 | 23,993.38 | 1,071.79 | 4.68% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,588.71 | 239.92 | 2.32% |
| HKSE | 25,845.24 | 728.71 | 2.90% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |